Welcome to PREDICT Consortium
Personalised RNA Interference to Enhance the Delivery of Individualised Cytotoxic and Targeted therapeutics
PREDICT will define the next generation of predictive biomarkers through the integration of clinical trial design with functional cancer genomics to enable personalised medicine and the cost-effective delivery of beneficial cancer therapeutics.
About the Consortium
The PREDICT Consortium was established in 2009 to coordinate single drug clinical trials with personalised tumour functional genomic analysis to define patient-specific drug sensitivity pathways and biomarkers predictive of drug response.
The consortium integrates expertise in renal carcinoma clinical trial recruitment, whole genome sequencing technologies, ex vivo cancer cell line cultures and personalised rna interference screening technologies.
Ocelot: a new web based research tool for renal cancer research
The PREDICT Consortium recently created Ocelot, a web-based tool for cancer researchers which enables efficient hypothesis-driven exploration of genomic data produced in clinical trials. Read more »
Latest News and Events
-
Dr. James Larkin from the Royal Marsden Hospital, a partner in the Predict project, is to give a key read more »
-
Thomson Reuters Web of Science, the company that also publishes the Impact Factor for scientific jou read more »
-
PREDICT Consortium results lead to invitation to discuss results at the Plenary session presentation read more »
PREDICT is utilising whole genome RNA interference screens to identify which genes encoded by the cancer genome influence response to common cytotoxic and targeted therapeutics used in clinical practice. 
PREDICT has initiated a series of single drug clinical trials in the pre-operative setting enabling tumour genomics analysis before and after treatment. The consortium is analysing clinical trial tumour tissue using whole genome sequencing and gene expression approaches in order to identify how tumour somatic mutations and gene expression changes evolve through therapy. 
PREDICT is employing technological developments to develop new cancer models for in vivo and in vitro therapeutic assessments and utilising novel bioinformatics approaches to develop platforms for biomarker discovery.